Lannett (NYSE:LCI) Coverage Initiated at StockNews.com

Analysts at StockNews.com began coverage on shares of Lannett (NYSE:LCIGet Rating) in a report issued on Wednesday. The firm set a “hold” rating on the stock.

Lannett Stock Up 6.3 %

Shares of Lannett stock opened at $0.52 on Wednesday. The stock has a market capitalization of $22.38 million, a P/E ratio of -0.09 and a beta of 0.94. The company has a 50-day simple moving average of $0.47 and a 200 day simple moving average of $0.53. Lannett has a 12-month low of $0.39 and a 12-month high of $2.16.

Lannett (NYSE:LCIGet Rating) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.04. The firm had revenue of $75.08 million during the quarter, compared to the consensus estimate of $68.23 million. On average, equities analysts anticipate that Lannett will post -1.61 earnings per share for the current year.

Institutional Trading of Lannett

A number of large investors have recently added to or reduced their stakes in LCI. Vanguard Group Inc. boosted its holdings in Lannett by 5.2% in the 3rd quarter. Vanguard Group Inc. now owns 740,875 shares of the company’s stock valued at $333,000 after purchasing an additional 36,690 shares during the period. Goldman Sachs Group Inc. lifted its stake in Lannett by 88.2% during the second quarter. Goldman Sachs Group Inc. now owns 43,408 shares of the company’s stock worth $25,000 after purchasing an additional 20,348 shares during the last quarter. Atria Wealth Solutions Inc. boosted its holdings in shares of Lannett by 115.2% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 304,700 shares of the company’s stock valued at $177,000 after purchasing an additional 163,110 shares in the last quarter. Staley Capital Advisers Inc. lifted its holdings in shares of Lannett by 10.7% in the second quarter. Staley Capital Advisers Inc. now owns 515,145 shares of the company’s stock worth $299,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Bailard Inc. bought a new stake in shares of Lannett during the second quarter worth $40,000. Institutional investors and hedge funds own 44.11% of the company’s stock.

Lannett Company Profile

(Get Rating)

Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages.

Further Reading

Receive News & Ratings for Lannett Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett and related companies with MarketBeat.com's FREE daily email newsletter.